We Believe Our Approach Has Created a Leading Pipeline of Multiple Drug and Development Candidates in Targeted Radiopharmaceutical Therapeutics
We have built a portfolio of potential RPT candidates that includes late-stage clinical programs, development programs and discovery programs. We only file an IND and advance programs beyond IND enabling studies and into formal clinical development once we have conducted rigorous preclinical evaluation.
Agent: RYZ101 | Target: SSTR2 | IND Enabling | Phase 1 | Phase 2 | Phase 3 | GEP-NETs* |
|---|---|---|---|---|---|
ES-SCLC | |||||
HR+/HER2-mBC | |||||
Agent: RYZ401 | Target: SSTR2 | IND Enabling | Phase 1 | Phase 2 | Phase 3 | GEP-NETs, solid tumor |
Agent: RYZ801/RYZ811 | Target: GPC3 | IND Enabling | Phase 1 | Phase 2 | Phase 3 | HCC |
Agent: RYZ701/RYZ711 | Target: ACP3 | IND Enabling | Phase 1 | Phase 2 | Phase 3 | Prostate Cancer |
RYZ701 Prostate Cancer | |||||
Agent: Pre-clinical | Target: Target | IND Enabling | Phase 1 | Phase 2 | Phase 3 | Pre-clinical ccRCC |
Multiple targets | |||||
| Agent: RYZ101 Target: SSTR2 |
|||
|---|---|---|---|
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | Action-1 GEP-NETs* |
| RYZ101-101 ES-SCLC | |||
| Tracy-1 HR+/HER2-mBC | |||
| Agent: RYZ401 Target: SSTR2 |
|||
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | RYZ401 GEP-NETs, solid tumor |
| Agent: RYZ801/RYZ811 Target: GPC3 |
|||
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | RYZ801-101 HCC |
| Agent: RYZ701/RYZ711 Target: ACP3 |
|||
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | RYZ711 Prostate Cancer |
| RYZ701 Prostate Cancer | |||
| Agent: Pre-clinical Target: Target |
|||
| IND Enabling | Phase 1 | Phase 2 | Phase 3 | Pre-clinical ccRCC |
| Pre-clinical Multiple targets | |||
*GEP-NETs expressing SSTR2 who are refractory to Lu177 SSA treatment.
